Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atricure Inc (NQ: ATRC )

22.49 +0.18 (+0.81%)
Streaming Delayed Price Updated: 11:35 AM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Atricure Inc

< Previous 1 2 Next >
Cracking The Code: Understanding Analyst Reviews For AtriCure
Via Benzinga
ATRC Stock Earnings: AtriCure Misses EPS, Beats Revenue for Q1 2024
ATRC stock results show that AtriCure missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Key Takeaways From AtriCure Analyst Ratings
Via Benzinga
Coinbase To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For AtriCure
Via Benzinga
Recap: AtriCure Q4 Earnings
Via Benzinga
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
AtriCure's Earnings: A Preview
Via Benzinga
Key Takeaways From AtriCure Analyst Ratings
Via Benzinga
Where AtriCure Stands With Analysts
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market
Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies’ (NASDAQ: BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in Ne 
Via Benzinga
What 7 Analyst Ratings Have To Say About AtriCure
Via Benzinga
Analyst Ratings for AtriCure
Via Benzinga
Earnings Outlook For AtriCure
Via Benzinga
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday
Morgan Stanley cut VTEX (NYSE: VTEX) price target from $7 to $5.  Morgan Stanley analyst Cesar Medina downgraded the stock from Overweight to Equal-Weight. VTEX shares fell 4.9% to close at $3.52 on... 
Via Benzinga
5 Analysts Have This to Say About AtriCure
Within the last quarter, AtriCure (NASDAQ:ATRC) has observed the following analyst ratings: 
Via Benzinga
AtriCure: Q2 Earnings Insights
AtriCure (NASDAQ:ATRC) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings AtriCure missed estimated earnings by... 
Via Benzinga
5 Analysts Have This to Say About AtriCure
Over the past 3 months, 5 analysts have published their opinion on AtriCure (NASDAQ:ATRC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Analyst Ratings for AtriCure
Over the past 3 months, 4 analysts have published their opinion on AtriCure (NASDAQ:ATRC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
AtriCure's Q1 EPS Miss Estimates, Needham Lowers Price Target
Needham lowered AtriCure Inc's (NASDAQ: ATRC) price target to $67 from $79 due to peer multiple compression, with the Buy rating unchanged. 
Via Benzinga
4 Analysts Have This to Say About AtriCure
Over the past 3 months, 4 analysts have published their opinion on AtriCure (NASDAQ:ATRC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
AtriCure: Q1 Earnings Insights
AtriCure (NASDAQ:ATRC) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings AtriCure missed estimated earnings by... 
Via Benzinga
AtriCure Reports Deeper Losses In Q4 Despite 27% Jump In Sales, Issues FY22 Guidance
AtriCure Inc (NASDAQ: ATRC) reported Q4 
Via Benzinga
Recap: AtriCure Q4 Earnings
AtriCure (NASDAQ:ATRC) reported its Q4 earnings results on Tuesday, February 15, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings AtriCure missed estimated earnings... 
Via Benzinga
The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage... 
Via Benzinga
A Preview Of AtriCure's Earnings
AtriCure (NASDAQ:ATRC) is set to give its latest quarterly earnings report on Tuesday, 2022-02-15. Here's what investors need to know before the announcement. Analysts estimate that AtriCure will... 
Via Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news... 
Via Benzinga
Earnings Scheduled For February 15, 2022
Companies Reporting Before The Bell • FirstService (NASDAQ:FSV) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.07 billion. 
Via Benzinga
AtriCure, inc (ATRC) Q3 2021 Earnings Call Transcript
ATRC earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.